Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 701–800 of 1,000
Pasvolsky, O., Milton, D. R., Rauf, M., Tanner, M. R., Bashir, Q., Srour, S. A., Tang, G., Saini, N. Y., Ramdial, J., Masood, A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.028 · Cited by 11
Merz, M., Kellermann, L., Poenisch, W., Tischler, H., Kohnke, J., Knauf, W. U., & Goldschmidt, H. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2991-0 · Cited by 12
“Combinations with proteasome inhibitors like bortezomib, carfilzomib [18] and ixazomib [11] increase response rates of Rd and improve progression-free survival (PFS).”
BackgroundParrondo, R. D., Roy, V., Sher, T., Alegria, V. R., Chanan-Khan, A. A., & Ailawadhi, S. (2020) · Case Reports in Hematology · doi:10.1155/2020/4360926 · Cited by 12
Che, F., Chen, J., Dai, J., & Liu, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s255682 · Cited by 12
Jreich, R., Zhang, H., Meng, Z., & Wang, F. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0164 · Cited by 11
An emergency medicine review: Multiple myeloma and its complications
Long, B., McCurdy, A. B. R., Koyfman, A., & Rosenberg, H. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.11.073 · Cited by 11
Hu, S., Xu, J., Cui, W., Jin, H.-R., Wang, X., & Maimaitiyiming, Y. (2025) · Biomolecules · doi:10.3390/biom15050702 · Cited by 11
“PIs such as bortezomib and carfilzomib prevent protein degradation in MM cells, inducing apoptosis [6–8].”
Targeting the Ubiquitin–Proteasome System for Cancer
Liu, Z., Lai, J., Ma, Z., Pan, J., Yang, C., & Fu, R. (2025) · MedComm · doi:10.1002/mco2.70391 · Cited by 14
“For elderly MM patients, two separate studies have shown the efficacy of lenalidomide and dexamethasone as a combined treatment [189].”
Cardio-oncological management of patients
Cardinale, D. M., Barac, A., Torbicki, A., Khandheria, B. K., Lenihan, D. J., & Minotti, G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.11.002 · Cited by 13
Quach, H., Nooka, A. K., Samoylova, O., Venner, C. P., Kım, K., Facon, T. T. F., Spencer, A. G., Usmani, S. Z., Grosicki, S., Suzuki, K., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17541 · Cited by 11
Self-citationDrug Repurposing by Tumor Tissue Editing
Lüke, F., Harrer, D. C., Pantziarka, P., Pukrop, T., Ghibelli, L., Gerner, C., Reichle, A., & Heudobler, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.900985 · Cited by 11
Gao, H., Chen, Z., Yao, Y., He, Y., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1453090 · Cited by 13
Nuances in the Management of Older People With Multiple Myeloma
Pawlyn, C., Gay, F., Larocca, A., Roy, V., & Ailawadhi, S. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0323-4 · Cited by 11
How is patient care for multiple myeloma advancing?
Stavric, S. G., Bonello, F., Bringhen, S., Boccadoro, M., & Larocca, A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1326814 · Cited by 12
“conventional and novel agents, including bortezomib [43,44].”
Pomalidomide Desensitization in a Patient Hypersensitive to Immunomodulating Agents
Seki, J. T., Sakurai, N., Lam, W., & Reece, D. E. (2017) · Current Oncology · doi:10.3747/co.24.3572 · Cited by 11
Richardson, P. G. G., Roy, A. N., Acharyya, S., Panneerselvam, A., Mendelson, E. T., Guenther, A., Lonial, S., & Einsele, H. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1369399 · Cited by 12
Standing up to the cardiometabolic consequences of hematological cancers
Howden, E. J., Gerche, A. L., Arthur, J. F., McMullen, J. R., Jennings, G., Dunstan, D. W., Owen, N. G., Avery, S., & Kingwell, B. A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.005 · Cited by 13
Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase
Holstein, S. A., Hillengaß, J., & McCarthy, P. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9637 · Cited by 11
Jun, Y., Xu, J., Kim, H., Park, J. E., Jeong, Y., Min, J. S., Yoon, N., Choi, J. Y., Yoo, J., Bae, S. K., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.01.008 · Cited by 11
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Maples, K. T., Joseph, N. S., & Harvey, R. D. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1828071 · Cited by 12
Richard, S., Jagannath, S., Cho, H. J., Parekh, S. S., Madduri, D., Richter, J. R., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1858790 · Cited by 11
López‐Candales, A., Mathur, P., & Thanendrarajan, S. (2020) · Heart Views · doi:10.4103/heartviews.heartviews_107_20 · Cited by 11
Thao, T., Vo, M.-C., Chu, T.-H., Kim, J. Y., Kim, C., Lee, J., Jung, S., & Lee, C. (2021) · Sensors · doi:10.3390/s21030836 · Cited by 11
“Combined with dexamethasone or lenalidomide and dexamethasone, carfilzomib has proven to significantly improve the survival outcomes of relapsed refractory MM patients in randomized phase 3 clinical trials [2].”
BackgroundMorabito, F., Zamagni, E., Conticello, C., Pavone, V., Palmieri, S., Bringhen, S., Galli, M., Mangiacavalli, S., Derudas, D., Rossi, E., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13723 · Cited by 11
Osterhoff, G., Kreinest, M., Kuhnt, T., Pohlenz, C., Müller-Broich, J. D., Röllig, C., Teipel, R., Scheyerer, M. J., Schnake, K. J., Spiegl, U. J. A., et al. (2023) · Global Spine Journal · doi:10.1177/21925682221143732 · Cited by 14
Moreau, P., Weisel, K. C., Song, K., Gibson, C. J., Saunders, O., Sternas, L. A., Hong, K., Zaki, M. H., & Dimopoulos, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1180685 · Cited by 13
“Aside from POMþ LoDEX,[12,13,22] addition of the second-generation proteasome inhibitor carfilzomib to LEN and dexamethasone has shown promise in early relapse based on the results of the ASPIRE trial in patients with relapsed MM who have received 1–3 prior treatments,[23] and the combination of histone deacetylase in…”
BackgroundSelf-citationZhao, F., Yang, B., Wang, J., Zhang, R., Liu, J., Yin, F., Xu, W., & He, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s159818 · Cited by 11
Milan, A., Bruno, G., Maffei, I., Iannaccone, A., Ravera, A., Schiavone, D., & Veglio, F. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180611110547 · Cited by 11
Contribution of Inhibition of Protein Catabolism in Myeloma
Bianchi, G., & Anderson, K. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000349 · Cited by 11
Neumaier, H. L., Harel, S., Klingel, K., Kaya, Z., Heuser, A., Kespohl, M., & Beling, A. (2020) · Cells · doi:10.3390/cells9051093 · Cited by 11
“Achievement of partially overlapping inhibition of the standard proteasome subunit β5 by ONX 0914 in cardiac tissue, as shown here, relates back to the observed cardiotoxicity, induced by marketed proteasome inhibitors for the treatment of multiple myeloma [59,60] by their inhibition of the cardiac proteasome complex.”
BackgroundGay, F., Günther, A., Offidani, M., Engelhardt, M. M., Salvini, M., Montefusco, V., Patriarca, F. F., Aquino, S., Pönisch, W., Spada, S., et al. (2021) · Cancer · doi:10.1002/cncr.33647 · Cited by 11
“ALT/AST/GGT increase 9 (14) 4 (6) — 1 (4) 2 (9)”
BackgroundInfluentialSelf-citationCarfilzomib for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma
Stewart, A. K. (2015) · Future Oncology · doi:10.2217/fon.15.123 · Cited by 11
Self-citationPourmoussa, A., Spielberger, R. T., Cai, J., Khoshbin, O., Farol, L. T., Cao, T. M., & Sahebi, F. (2019) · The Permanente Journal · doi:10.7812/tpp/19.012 · Cited by 12
“Median age at diagnosis, y (range) 57 (30-70) 60 (33-68) 0.”
BackgroundDevelopment of Proteasome Inhibitors for Cancer Therapy
Chen, X., Wu, X., Li, L., & Zhu, X. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100004 · Cited by 12
“Furthermore, the findings of its phase III clinical study demonstrated that carfilzomib is effective in patients who have had a relapse and are resistant to bortezomib [54, 55].”
BackgroundSheng, Z., Li, G., Li, B., Liu, Y., & Wang, L. (2017) · European Journal of Haematology · doi:10.1111/ejh.12877 · Cited by 10
“For those relapsed/refractory patients, the trial by Stewart had found that carfilzomib added to lenalidomide and dexamethasone could significantly improved response and progression-free survival(PFS), and had a favorable risk-benefit profile [5].”
BackgroundLiu, L., Zhao, N., Xu, W., Sheng, Z., & Wang, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0286-x · Cited by 11
“Furthermore, the addition of carfilzomib to lenalidomide (LEN) and dexamethasone could improve progression free survival by 31 % [10].”
BackgroundSriram, H., Kunjachan, F., Khanka, T., Gawai, S., Ghogale, S., Deshpande, N., Girase, K., Patil, J., Chatterjee, G., Rajpal, S., et al. (2022) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22099 · Cited by 10
Astarita, A., Mingrone, G., Airale, L., Cesareo, M., Colomba, A., Catarinella, C., Leone, D., Gay, F., Bringhen, S., Veglio, F., et al. (2023) · Cancers · doi:10.3390/cancers15030955 · Cited by 10
“Similarly, the ASPIRE study demonstrated the superiority of KRd (K administered at the dose of 20 mg/m2 on days one and two, and at 27 mg/m2 thereafter) versus lenalidomide-dexamethasone in PFS and disease response [9].”
BackgroundMethodRavichandran, S., Hall, A., Jenner, M. W., Garg, M. K., Kishore, B., Lachmann, H. J., Gillmore, J. D., Pitchford, A., Oughton, J. B., Mahmood, S., et al. (2023) · Amyloid · doi:10.1080/13506129.2023.2169124 · Cited by 10
“The toxicity profile in the present study is comparable to previous reports [15,20].”
ResultCarfilzomib-associated thrombotic microangiopathy: clinical features and outcomes
Joseph, A., Harel, S., Mesnard, L., Rafat, C., Knapp, S., Rumpler, A., Philipponnet, C., Barba, C., Rebibou, J.-M., Buob, D., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae096 · Cited by 10
Advancements in the Treatment of Multiple Myeloma
Zavaleta‐Monestel, E., Quesada-Villaseñor, R., Barrantes-López, M., Arguedas‐Chacón, S., Campos-Hernández, J., Rojas-Chinchilla, C., García-Montero, J., Castro-Ulloa, J., Anchía-Alfaro, A., & Montenegro-Chaves, J. R. (2024) · Cureus · doi:10.7759/cureus.74970 · Cited by 12
Dong, S., Banerjee, R. K., Khan, A. M., Wang, M., Wang, X., Afghahi, A., Afrough, A., Janakiram, M., Wang, B., Cowan, A. J., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01256-2 · Cited by 10
Self-citationLeleu, X. P., Terpos, E., García‐Sánz, R., Cooney, J. P., O’Gorman, P., Minařík, J., Greil, R., Williams, C. D., Gray, D., & Szabó, Z. R. (2016) · American Journal of Hematology · doi:10.1002/ajh.24416 · Cited by 11
Treatment of Relapsed/Refractory Multiple Myeloma
Neri, P. E., Bahlis, N. J., Paba‐Prada, C. E., & Richardson, P. G. G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_10 · Cited by 10
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Cerchione, C., Nappi, D., & Martinelli, G. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06266-x · Cited by 10
Siegel, D. S. D., Weisel, K. C., Zahlten‐Kumeli, A., Medhekar, R., Ding, B., & Leleu, X. P. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1941927 · Cited by 11
Self-citationDu, J., Fang, B., Li, J., Jin, J., Wang, S., Zou, D., Cai, Z., Wang, H., Hu, J., Li, W., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03044-z · Cited by 10
“) of carfilzomibbased regimens [13, 18, 22], which also allowed carfilzomib treatment for up to 72 weeks (ASPIRE) or to progression (ENDEAVOR, A.”
BackgroundDimopoulos, M. A., Mikhael, J. R., Terpos, E., Leleu, X. P., Moreau, P., Bladé, J., Kim, J. S., Stockerl-Goldstein, K. E., & Richardson, P. G. G. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221088458 · Cited by 10
Self-citationLeleu, X. P., Katodritou, E., Kuehr, T., Terpos, E., Caers, J., Zambello, R., Brescianini, A., Liang, T., Wetten, S., & BADELITA, S. N. (2022) · eJHaem · doi:10.1002/jha2.595 · Cited by 11
“The combination also showed a favourable risk-benefit profile [14].”
BackgroundMethodResultInfluentialBreaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Solimando, A. G., Krebs, M., Desantis, V., Marziliano, D., Caradonna, I. C., Morizio, A., Argentiero, A., Shahini, E., & Bittrich, M. (2023) · Biomedicines · doi:10.3390/biomedicines11072087 · Cited by 13
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Ray, E. L., Jagannath, S., & Palumbo, A. P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1119041 · Cited by 10
Self-citationClark, C. A., Cornell, R. F., Scott, E. C., Chung, J., & Costa, L. J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24478 · Cited by 10
“The Aspire trial limited enrollment to patients with CrCl >50 ml/min[15], therefore no information is available on the benefit of KRd over Rd for patients with significant renal dysfunction.”
BackgroundInfluentialSafety issues and management of toxicities associated with new treatments for multiple myeloma
Brioli, A., Mügge, L., Hochhaus, A., & von Lilienfeld‐Toal, M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1284584 · Cited by 11
“Of note, patients receiving KRd treatment reported a superior health-related quality of life [2].”
BackgroundMethodInfluentialWeberpals, J. G., Pulte, D. D., Jansen, L., Luttmann, S., Holleczek, B., Nennecke, A., Ressing, M., Katalinic, A., Merz, M., & Brenner, H. (2017) · Haematologica · doi:10.3324/haematol.2016.157768 · Cited by 10
Ixazomib in the Management of Relapsed Multiple Myeloma
Touzeau, C., & Moreau, P. (2018) · Future Oncology · doi:10.2217/fon-2017-0710 · Cited by 10
Self-citationCampioni, M., Agirrezabal, I., Hájek, R., Minařík, J., Pour, L., Spicka, I., Gonzalez‐McQuire, S., Jandová, P., & Maisnar, V. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01122-6 · Cited by 10
Self-citationNew regimens and directions in the management of newly diagnosed multiple myeloma
Bal, S., Giri, S., Godby, K. N., & Costa, L. J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26080 · Cited by 11
“Carfilzomib outperformed bortezomib in the relapsed setting(28) and, when combined with lenalidomide and dexamethasone (RD), improved ORR, PFS, and OS over RD alone.(7,29)”
BackgroundSteinmetz, T., Singh, M., Lebioda, A., Fink, L., Schoehl, M., Rieth, A., Gonzalez‐McQuire, S., & Engelhardt, M. M. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2020.1867469 · Cited by 10
“n (%) 219 (100) 92 (42) 106 (48) 21 (10) 83 (100) 12 (15) 51 (61) 20 (24) Mean age at diagnosis, years 67 72 64 64 67 65 68 65 Male, n (%) 152 (69) 65 (71) 71 (67) 16 (76) 58 (70) 8 (67) 36 (62) 14 (24) ECOG performance status 0–1 at index PI line, n (%) 118 (54) 39 (42) 64 (60) 15 (71) 48 (58) 7 (58) 29 (60) 12 (60)…”
Hotta, M., Ito, T., Konishi, A., Yoshimura, H., Nakanishi, T., Fujita, S., Satake, A., & Nomura, S. (2021) · Internal Medicine · doi:10.2169/internalmedicine.5646-20 · Cited by 11
“After surgery, carfilzomib-lenalidomidedexamethasone (CLd) therapy [with at a dose and schedule according to the ASPIRE protocol (9)] was started.”
MethodLahuerta, J. J., Paiva, B., Ubieto, A. J., Sánchez-Pina, J. M., Mateos, M., Bladé, J., & Miguel, J. F. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003996 · Cited by 10
Self-citationKim, K. B. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.27 · Cited by 12
Kobayashi, T., Miura, M., Niioka, T., Abumiya, M., Ito, F., Kobayashi, I., Ikeda, S., Yoshioka, T., Kameoka, Y., & Takahashi, N. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000499 · Cited by 10
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Park, J., Park, E., Jung, C.-K., Kang, S.-W., Kim, B. G., Jung, Y., Kim, T. H., Lim, J.-Y., Lee, S.-E., Min, C.-K., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2285-2 · Cited by 9
Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282624 · Cited by 9
Self-citationBerenson, J. R., Kim, C., Bujarski, S., To, J., Spektor, T. M., Martinez, D., Turner, C., Ghermezi, M., Eades, B. M., Swift, R. A., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3066 · Cited by 9
Pomalidomide in the Management of Relapsed Multiple Myeloma
Touzeau, C., & Moreau, P. (2016) · Future Oncology · doi:10.2217/fon-2016-0184 · Cited by 9
Self-citationDisease Milestones through Bibliometric Analysis of the Top 100 Cited Articles in Multiple Myeloma
Latif, A., Kapoor, V., Sipra, Q. U. A. R., Malik, S. U., Bilal, J., Riaz, I. B., & Faiz, A. (2018) · Cureus · doi:10.7759/cureus.2438 · Cited by 10
“Studies 2012, and onwards were focused on latest developments in the field of MM including therapeutic agents such as novel proteasome inhibitors (carfilzomib, ixazomib), monoclonal antibodies (daratumumab, elotuzumab), and chimeric antigen receptor T cell therapy [7-11].”
Multiple myeloma – 2020 update on diagnosis and management
Charliński, G., & Jurczyszyn, A. J. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2020.0035 · Cited by 10
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers
Zagirova, D., Autenried, R., Nelson, M. E., & Rezvani, K. S. (2021) · Journal of Cancer · doi:10.7150/jca.52414 · Cited by 9
“resistance by targeting multiple β catalytic subunits in an irreversible manner alongside enhanced oral availability [15].”
BackgroundKawaji‐Kanayama, Y., Kobayashi, T., Muramatsu, A., Uchiyama, H., Sasaki, N., Uoshima, N., Nakao, M., Takahashi, R., Shimura, K., Kaneko, H., et al. (2021) · Cancer Reports · doi:10.1002/cnr2.1476 · Cited by 9
Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4
Ma, N., Liu, H., Zhang, Y., Liu, W., Liang, Z., Wang, Q., Yuhua, S., Wang, L., Li, Y., Ren, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927804 · Cited by 9
“The past decade witnessed great progress in multiple myeloma (MM) management, including new agents such as proteasome inhibitors (1, 2) and immuno-modulators (3, 4), immunotherapy targeting myeloma cells such as the monoclonal antibodies targeting CD38 (5) and SLAMF7 (CS-1) (6), antiBCMA chimeric antigen receptor T (C…”
BackgroundCardiovascular toxicity from therapies for light chain amyloidosis
Morfino, P., Aimo, A., Castiglione, V., Chianca, M., Vergaro, G., Cipolla, C. M., Fedele, A., Emdin, M., Fabiani, I., & Cardinale, D. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1212983 · Cited by 9
“The phase III ASPIRE trial, which compared the effects of carfilzomib with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone in patients (n = 792) with relapsed MM, found that the carfilzomib group had better progression-free survival but enhanced frequency of CTR-CT (92).”
BackgroundInfluentialAn update on the use of lenalidomide for the treatment of multiple myeloma
Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067681 · Cited by 11
Self-citationRaedler, L. A. (2016) · Europe PMC (PubMed Central) · Cited by 9
Iida, S., Tobinai, K., Taniwaki, M., Shumiya, Y., Nakamura, T., & Chou, T. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2070-7 · Cited by 9
“In the United States, carfilzomib was first approved in July 2012 through the accelerated approval program for patients with MM with at least two previous treatments, including those with bortezomib and immunomodulatory agents, on the basis of phase II data [5], and subsequently carfilzomib was approved in July 2015 a…”
BackgroundMethodIida, S., Wakabayashi, M., Tsukasaki, K., Miyamoto, K., Maruyama, D., Yamamoto, K., Takatsuka, Y., Kusumoto, S., Kuroda, J., Ando, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13550 · Cited by 9
“3 months, respectively.(15,19,20) In addition, the median PFS of BD in combination with panobinostat, a histone deacetylase inhibitor, was reported to be 12.”
BackgroundHari, P., Lin, H. M., Zhu, Y., Berg, D. T., Richardson, P. G. G., & Moreau, P. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1474745 · Cited by 9
Self-citationDose Selection for Multiple Myeloma in Modern Era
Wang, S., Salgado, L. R., Adler, A., Chang, S., Ru, M., Moshier, E. L., Dharmarajan, K. V., Cho, H. J., & Bakst, R. L. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.02.009 · Cited by 9
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders
Smolewski, P., & Rydygier, D. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1596258 · Cited by 9
Mian, H. S., Fiala, M. A., Sanchez, L. J., Vij, R., & Wildes, T. M. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04420-3 · Cited by 9
Cancer Therapies and Vascular Toxicities
Meilhac, A., Cautela, J., & Thuny, F. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00964-2 · Cited by 10
Steps towards a Multiple Myeloma Cure?
Gozzetti, A., & Bocchia, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091451 · Cited by 9
Elbezanti, W. O., Al‐Odat, O. S., Chitren, R. J., Singh, J. K., Srivastava, S. K., Gowda, K., Amin, S., Robertson, G. P., Nemmara, V. V., Jonnalagadda, S. C., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894535 · Cited by 9
“In addition to CD138, Nanog, Myc, OCT4, and GLI1 are all-present on CD138 cells and can be used as additional markers of stemness (Zhou et al., 2014; Stewart et al., 2015).”
BackgroundLee, J. H., Kim, S., Kim, H. R., Min, C., Lee, J., Shin, H., Jo, J., Lee, J. Y., Moon, J. H., & Kım, K. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03479-6 · Cited by 9
Should minimal residual disease negativity be the end point of myeloma therapy?
Anderson, K. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000117 · Cited by 12
Ninkovic, S., & Quach, H. (2020) · Cancers · doi:10.3390/cancers12113488 · Cited by 9
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9
“netic risk factors, t(4;14) and del(17p) [46,47].”
Cowan, A. J., Green, D. J., Karami, M., Becker, P. S., Tuazon, S. A., Coffey, D. G., Hyun, T. S., Libby, E. N., Gopal, A. K., & Holmberg, L. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.002 · Cited by 9
The molecular biology of multiple myeloma
Chng, W. J., & Bergsagel, P. L. (2019) · Wiley eBooks · doi:10.1002/9781119252863.ch10 · Cited by 9
What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma
D’Souza, A., & Lonial, S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01137 · Cited by 9
Dai, Y., Guo, X., & Yang, C. (2020) · Oncology Letters · doi:10.3892/ol.2020.11678 · Cited by 8
Visram, A., Chan, K., Seow, H. Y., Pond, G. R., Gayowsky, A., Mohyuddin, G. R., McCurdy, A. B. R., Sandhu, I., Venner, C. P., Lancman, G., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285768 · Cited by 11
Lee, B. J., Sayer, M., Naqvi, A., Mai, K. T., Patel, P. M., Lee, L. X., & Ozaki, A. F. (2025) · eJHaem · doi:10.1002/jha2.70038 · Cited by 9
Chang, W.-H., Liao, W., Yeh, T., Moi, S., Liu, Y., Hsiao, H., Wang, H., Du, J., Gau, Y., Yang, C.-I., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07252-1 · Cited by 8
Sequencing of nontransplant treatments in multiple myeloma patients with active disease
Yee, A. J., & Raje, N. S. (2016) · Hematology · doi:10.1182/asheducation-2016.1.495 · Cited by 8
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
Bobin, A., Gruchet, C., Guidez, S., Gardeney, H., Nsiala, L., Vonfeld, M., Lévy, A., Cailly, L., Sabirou, F., Systchenko, T., et al. (2021) · Cancers · doi:10.3390/cancers13205210 · Cited by 9
Morabito, F., Zamagni, E., Conticello, C., Pavone, V., Palmieri, S., Bringhen, S., Galli, M., Mangiacavalli, S., Derudas, D., Rossi, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890376 · Cited by 8
“, their immunomodulatory effects through the induction of NK cell activation and boosted ADCC activity (15), indicated IMiDbased protocols as intriguing backbone doublets to be integrated, in triplet regimens, with the second-class proteasome inhibitor carfilzomib (KRd) (16, 17), or with two primary monoclonal”
BackgroundMethodOral ixazomib maintenance therapy in multiple myeloma
Offidani, M., Corvatta, L., Gentili, S., Maracci, L., & Leoni, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123627 · Cited by 9
Harousseau, J., & Mohty, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6 · Cited by 9
Terpos, E., Gobbi, M., Potamianou, A., Lahaye, M., Couturier, C., & Cavo, M. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12937 · Cited by 8
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.